Coeptis Therapeutics (COEP) files Form 25 to delist warrants from Nasdaq
Rhea-AI Filing Summary
Coeptis Therapeutics Holdings, Inc. notified Nasdaq of the removal of its warrants from listing and registration under Section 12(b) via Form 25. The filing states the Exchange and the Issuer complied with rules governing voluntary withdrawal and Nasdaq certified its grounds for the Form 25 filing.
Positive
- None.
Negative
- None.
Key Figures
Commission File Number: 001-39669
Document expiry reference: March 31, 2018
Issuer address zip: 33139
3 metrics
Commission File Number
001-39669
Form 25 cover identification
Document expiry reference
March 31, 2018
Expires line at document header
Issuer address zip
33139
Principal executive offices address
Key Terms
Form 25, 17 CFR 240.12d2-2, withdrawal of registration
3 terms
Form 25 regulatory
"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
17 CFR 240.12d2-2 regulatory
"Pursuant to 17 CFR 240.12d2-2(b) the Exchange has complied"
A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.
withdrawal of registration regulatory
"voluntary withdrawal of the class of securities from listing and registration"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Coeptis (COEP) Form 25 mean for its warrants?
It means Nasdaq has been notified to remove the company’s warrants from listing and registration. The filing states the Exchange and Issuer complied with rules for voluntary withdrawal; it does not provide trading suspension details or subsequent listing plans.
Will Coeptis (COEP) common stock be affected by this Form 25?
The Form 25 in this excerpt addresses the company’s warrants only. It does not state any change to common stock listing or registration. Any effect on other securities is not mentioned in the provided text.
Who certified the Form 25 filing for Coeptis (COEP)?
Nasdaq Stock Market LLC certified the notification and it was signed on behalf of the Exchange by Tara Petta, AVP. The filing states Nasdaq believes it meets requirements to file the Form 25 under the Exchange Act.
Does the Form 25 excerpt state a reason for the warrants' removal?
The excerpt cites compliance with rules for voluntary withdrawal under 17 CFR 240.12d2-2 but does not provide a specific business or operational reason for removing the warrants from Nasdaq listing.
Where is Coeptis Therapeutics' principal office listed in the filing?
The filing lists the Issuer’s principal executive offices at 801 S. Pointe Drive, Suite TH-1, Miami Beach, FL 33139 and provides a telephone number. This is provided as contact information in the Form 25.